Kyntra Bio (NASDAQ:KYNB) Stock Price Down 1.3% – Here’s What Happened

Kyntra Bio Inc (NASDAQ:KYNB)’s stock price traded down 1.3% during trading on Monday . The stock traded as low as $7.02 and last traded at $7.08. 28,374 shares traded hands during mid-day trading, a decline of 4% from the average session volume of 29,707 shares. The stock had previously closed at $7.17.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen cut Kyntra Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Zacks Research cut Kyntra Bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. HC Wainwright raised Kyntra Bio to a “strong-buy” rating in a report on Friday, February 27th. Finally, Weiss Ratings assumed coverage on Kyntra Bio in a report on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold”.

Kyntra Bio Trading Down 1.3%

The business has a 50 day simple moving average of $7.25. The firm has a market capitalization of $28.67 million, a P/E ratio of 0.16 and a beta of 0.90.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.